Background
Globally Staphylococcus aureus is one of the most frequent causes of hospital-acquired and community-acquired blood stream infections. 1 Although there are a wide variety of manifestations of serious invasive infection caused by S. aureus, in the great majority of these cases the organism can be detected in blood cultures. Therefore, S. aureus bacteraemia (SAB) is considered a very useful marker for serious invasive infection. 2 Although prolonged antimicrobial therapy and prompt source control are used to treat SAB, 3 mortality ranges from as low as 2.5% to as high as 40%. [4] [5] [6] Mortality rates, however, are known to vary significantly with patient age, clinical manifestation, comorbidities and methicillin resistance. 7, 8 A prospective study of SAB conducted in 27 laboratories in Australia and New Zealand found a 30-day all-cause mortality of 20.6%. 9 On univariate analysis increased mortality was significantly associated with older age, European ethnicity, methicillin resistance, infections not originating from a medical device, sepsis syndrome, pneumonia/empyema and treatment with a glycopeptide or other nonβ-lactam antibiotic.
The Australian Group on Antimicrobial Resistance (AGAR), a network of laboratories located across Australia, commenced surveillance of antimicrobial resistance in S. aureus in 1986. 10 In 2013 AGAR commenced the Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP). 11 The primary objective of ASSOP 2017 was to determine the proportion of SAB isolates demonstrating antimicrobial resistance with particular emphasis on:
1. Assessing susceptibility to methicillin 2. Molecular epidemiology of methicillin-resistant S. aureus (MRSA).
Methodology Participants
Thirty-six laboratories from all eight Australian states and mainland territories.
Collection Period
From 1 January to 31 December 2017, the 36 laboratories collected all S. aureus isolated from blood cultures. S. aureus with the same antimicrobial susceptibility profiles isolated from a patient's blood culture within 14 days of the first positive culture were excluded. A new S. aureus sepsis episode in the same patient was recorded if it was identified by a culture of blood collected more than 14 days after the last positive culture. Data were collected on age, sex, date of admission and discharge (if admitted), and mortality at 30 days from date of first positive blood culture.
To avoid interpretive bias, no attempt was made to assign attributable mortality. Each episode of bacteraemia was designated healthcare onset if the first positive blood culture(s) in an episode were collected >48 hours after admission.
Laboratory Testing
Participating laboratories performed antimicrobial susceptibility testing using the 12 and European Committee on Antimicrobial Susceptibility Testing (EUCAST) 13 breakpoints were utilised for interpretation. Isolates with a resistant or an intermediate category were classified as non-susceptible. Linezolid and daptomycin non-susceptible isolates were retested by Etest ® (bioMérieux) using the Mueller-Hinton agar recommended by the manufacturer. S. aureus ATCC 29213 was used as the control strain. High level mupirocin resistance was determined by the Phoenix™ or by using a mupirocin 200 μg disk according to CLSI guidelines on all isolates with a mupirocin MIC >8 mg/L by Vitek2 ® . Multi-resistance was defined as resistance to three or more of the following non-β-lactam antimicrobials: vancomycin, teicoplanin, erythromycin/clindamycin, tetracycline, ciprofloxacin, gentamicin, cotrimoxazole, fusidic acid, rifampicin, high level mupirocin, and linezolid.
Molecular testing was performed by whole genome sequencing (WGS) using the MiSeq platform (Illumina, San Diego, USA). Sequencing results were analysed using the Nullarbor pipeline. 14 The online spa typing tool described by Bartels et al. 15 was applied to determine spa types. SCCmec elements were identified using SCCmec sequences described by Monecke et al. 16 Chi-square tests for comparison of two proportions and calculation of 95% confidence intervals (95%CI) were performed using MedCalc for Windows, version 12.7 (MedCalc Software, Ostend Belgium).
Approval to conduct the prospective data collection was given by the research ethics committee associated with each participating laboratory.
Results
From 1 January to 31 December 2017, a total of 2,515 unique episodes of S. aureus bacteraemia were identified. A significant difference (p<0.001) was seen in patient sex with 66.5% (1,673) being male (95% CI 64. 6-68.3 
Methicillin-Susceptible Staphylococcus aureus (MSSA) Antimicrobial Susceptibility
Overall 81.0% (2,037) of the 2,515 isolates were methicillin susceptible of which 77.2% (1, 572) were penicillin resistant (MIC >0.12 mg/L). However as β-lactamase was detected in 62 phenotypically penicillin susceptible isolates, 80.3% of MSSA were considered penicillin resistant. Apart from erythromycin non-susceptibility (12.4%), resistance to the non-β-lactam antimicrobials amongst MSSA was rare, ranging from 0% to 3.3% (Table 1 ). There were ten isolates reported by Vitek2 ® as non-susceptible to daptomycin (MIC >1.0 mg/L). By Etest ® , six of the isolates were considered susceptible (MICs 0.38-1.0 mg/L). Four isolates had Etest ® MICs of 1.5-2.0 and therefore were considered non-susceptible. Using WGS, daptomycin non-susceptibility in two isolates was due to single point mutations in the mprF gene: mprF-I420T and mprF-L826I. No known single point mutations were identified in two isolates. By Vitek2 ® , two isolates were linezolid resistant (MIC >4 mg/L). However by Etest ® , the isolates had MIC ≤4 mg/L (3.0 mg/L) and were therefore considered linezolid susceptible. When using the EUCAST resistant breakpoint of >2 mg/L, four isolates were teicoplanin resistant (MIC = 4 mg/L). However, using the CLSI resistant breakpoint of >8 mg/L, the isolates were classified as susceptible. All MSSA were vancomycin susceptible. Thirty (1.5%) of 2,035 isolates had high-level mupirocin resistance of which 21 isolates were referred from Queensland. Seventeen of the thirty mupirocin resistant MSSA were also resistant to fusidic acid. Inducible resistance to clindamycin was determined by the Vitek2 ® susceptibility system. Of the 2,218 isolates tested, 14% (311) were erythromycin non-susceptible / clindamycin intermediate / susceptible (CLSI breakpoints) of which 85.2% (265) were classified as having inducible clindamycin resistance. Multiresistance was uncommon in MSSA (0.5%, 9/1,983).
There were no significant differences in antimicrobial interpretation when CLSI or EUCAST non susceptibility breakpoints were utilised (p>0.05).
MRSA Antimicrobial Susceptibility
The proportion of S. aureus that were MRSA was 19.0% (95% CI 17.5-20.6). Of the 478 MRSA identified 418 were cefoxitin screen positive by Vitek2 ® and 58 had a cefoxitin MIC >4 by Phoenix™. Two isolates were cefoxitin screen Multi-resistance was seen in 31.3% of MRSA.
There were no significant differences in interpretation for any drug when CLSI or EUCAST non-susceptibility breakpoints were utilised.
MRSA Molecular Epidemiology
WGS was performed on 96.7% (462/478) of the MRSA. Based on molecular typing, 25.5% (118) and 74.5% (344) of isolates were identified as healthcare-associated MRSA (HA-MRSA) and community-associated MRSA (CA-MRSA) clones respectively (Table 3 ). (Table 4 ) and were resistant to the β-lactams. Two of the three isolates were additionally resistant to fusidic acid. All were PVL negative.
Healthcare-associated methicillinresistant Staphylococcus aureus

Community-associated methicillinresistant Staphylococcus aureus
For the 344 CA-MRSA isolates, 24.4% (84) of episodes were epidemiologically classified as hospital-onset and 75.6% (260) classified as community-onset. Based on the multi (Table 3) . Overall, 71.5% of CA-MRSA were classified into five clones each having more than ten isolates: ST93-IV [2B] (Queensland CA-MRSA) (24.5% of MRSA typed and 4.5% of S. aureus); ST45-V T (9.4% and 1.7%); ST5-IV (8.4% and 1.6%); ST1-IV (7.4% and 1.4%); and ST78-IV (3.5% and 0.6%). ST45-V T accounted for 12.8% of CA-MRSA and was isolated primarily in New South Wales and Victoria ( Table 5 ). All isolates were PVL negative and were resistant to the β-lactams. Isolates were additionally non-susceptible to ciprofloxacin, erythromycin, gentamicin and tetracycline (37.2%, 16/43); ciprofloxacin, gentamicin and tetracycline (16.3%, 7/43); ciprofloxacin, erythromycin and gentamicin (11.6%, 5/43); ciprofloxacin, erythromycin and tetracycline (9.3%, 4/43); ciprofloxacin (7.0% 3/43); ciprofloxacin and erythromycin (4.7%, 2/43). Single isolates were resistant to either ciprofloxacin and gentamicin; ciprofloxacin and rifampicin; ciprofloxacin and tetracycline; ciprofloxacin, tetracycline and fusidic acid; ciprofloxacin, erythromycin, tetracycline and co-trimoxazole; or ciprofloxacin, erythromycin, tetracycline and high-level mupirocin. Overall 61.4% of ST45-V T were community-onset.
ST93-IV [2B] (Queensland
ST5-IV accounted for 11.3% of CA-MRSA and was isolated in all regions of Australia except the Australian Capital Territory ranging from 0% to 18.1% in Queensland (Table 5 ). ST5-IV, of which 23% were PVL positive, was typically resistant to the β-lactams only 43.6% (17/39); to β-lactams and co-trimoxazole (30.8%, 12/39); or additionally resistant to either erythromycin; fusidic acid; high-level mupirocin; or gentamicin and high-level mupirocin. Overall 66.7% of ST5-IV were community-onset.
ST1-IV accounted for 9.9% of CA-MRSA ranging from 1.4% in New South Wales to 100% in Tasmania ( Table 5 ). Typically PVL negative, 48.4% of isolates were resistant to the β-lactams only (15/31) or additionally resistant to erythromycin (25.8%, 8/31); fusidic acid (9.7%, 3/31); erythromycin and fusidic acid (6.5%, 2/31). Single isolates were resistant to either ciprofloxacin; erythromycin and tetracycline; or gentamicin and high-level mupirocin. Overall 76.5% of ST1-IV were community-onset.
ST78-IV accounted for 4.7% of CA-MRSA and was predominantly isolated in Western Australia (Table 5 ). Isolates were resistant to the β-lactams and erythromycin (87.5%, 14/16); one isolate resistant to the β-lactams only; and one isolate additionally resistant to high-level mupirocin.
Overall 81.3% of ST78-IV were communityonset.
Overall 85.3% of CA-MRSA were non-multiresistant including 43.5% resistant to the β-lactams only. However 50 (14.7%) CA-MRSA isolates were multi-resistant, a significant increase from ASSOP 2016 (7.7%, p=0.01). 17 Multi-resistance was primarily due to the ST45-V T clone.
Panton-Valentine leucocidin:
Overall 171 (37.0%) MRSA were PVL positive, including 49.7% of CA-MRSA (Table 3 ).
Discussion
The AGAR surveillance programmes collect data on antimicrobial resistance, focussing on bloodstream infections caused by S. aureus, Enterococcus and Enterobacteriaceae. All data collected in the AGAR programs are generated as part of routine patient care in Australia, with most available through laboratory and hospital bed management information systems. Isolates are referred to a central laboratory where strain and antimicrobial resistance determinant characterisation is performed. As the programmes are similar to those conducted in Europe, 18 comparison of Australia antimicrobial resistance data with other countries is possible.
In ASSOP 2017, 19 A decrease in methicillin-resistant SAB is consistent has been reported in several parts of the world 19, 20 and is believed to be due to the implementation of antimicrobial stewardship and a package of improved infection control procedures including hand hygiene, MRSA screening and decolonisation, patient isolation and infection prevention care bundles. [21] [22] [23] [24] [25] In Australia although we have not seen a decrease in MRSA bacteraemia we have observed significant decreases in HA-MRSA from 41.0% to 25.5% (p<0.001) and hospital-onset MRSA from 38.0% to 29.9% (p=0.02) over the five ASSOP surveys. 11, 17, 26, 27 Over the same time period we have observed a significant increase in CA-MRSA from 59.0% to 74.5% (p<0.001) and communityonset MRSA from 61.1% to 70.1% (p=0.008).
Because of the increased burden of CA-MRSA bacteraemia in Australia a significant reduction in the overall proportion of SAB due to MRSA may prove problematic.
In ASSOP 2017 the all-cause mortality at 30 (Aus-2/3 EMRSA) as the most prevalent HA-MRSA isolated from clinical specimens and this change has occurred throughout most of the country. 28 In ASSOP 2017 approximately 20% of MRSA were characterised as ST22-IV [2B] (EMRSA-15). CA-MRSA, in particular the ST45-V T clone (9.5% of MRSA), has acquired multiple antimicrobial resistance determinants including ciprofloxacin, erythromycin, clindamycin, gentamicin and tetracycline.
Resistance was not detected for vancomycin, linezolid or teicoplanin when CLSI interpretive criteria were applied. However five isolates were teicoplanin non-susceptible when EUCAST criteria were applied. There were six isolates resistant to daptomycin by both CLSI and EUCAST criteria.
Approximately 24.4% of SAB caused by CA-MRSA were healthcare-onset. Transmission of CA-MRSA in Australian hospitals is thought to be rare. 29, 30 It is likely that many of the healthcare onset CA-MRSA SAB infections reported in ASSOP 2017 were caused by the patient's own colonising strains acquired prior to admission. In Australia CA-MRSA clones such as PVLpositive ST93-IV [2B] (Queensland CA-MRSA) are well established in the community and therefore it is important to monitor antimicrobial resistance patterns in both community and healthcare-associated SAB as this information will guide therapeutic practices in treating S. aureus sepsis.
In conclusion, ASSOP 2017 has demonstrated antimicrobial resistance in SAB in Australia continues to be a significant problem and continues to be associated with a high mortality.
This may be due, in part, to the high prevalence of methicillin-resistant SAB in Australia, which is significantly higher than most EU/EEA countries. Consequently MRSA must remain a public health priority and continuous surveillance of SAB and its outcomes and the implementation of comprehensive MRSA strategies targeting hospitals and long-term care facilities are essential.
